Valuation: AstraZeneca PLC

Market Cap 244B 217B 203B 184B 347B 23,589B 350B 2,429B 951B 12,022B 915B 895B 38,473B P/E 2026 *
20.3x
P/E 2027 * 17.4x
Enterprise Value 263B 235B 219B 199B 375B 25,491B 379B 2,625B 1,028B 12,992B 989B 967B 41,576B EV / Sales 2026 *
4.17x
EV / Sales 2027 * 3.81x
Free-Float
96.62%
Yield 2026 *
2.13%
Yield 2027 * 2.26%
1 day-2.36%
1 week-3.16%
Current month-3.16%
1 month-1.25%
3 months-17.21%
6 months-20.50%
Current year-13.76%
1 week 11,716
Extreme 11716
12,180
1 month 11,552
Extreme 11552
12,788
Current year 10,524
Extreme 10524
15,732
1 year 10,524
Extreme 10524
15,732
3 years 9,461
Extreme 9461
15,732
5 years 8,090.32
Extreme 8090.32
15,732
10 years 3,996
Extreme 3996
15,732
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Chief Operating Officer 55 01/06/2015
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
9/14/26 A Free

Chief Financial Officer

73 0.0000%
9/14/26 A Buy

Chairman

2,500 0.0002%
9/14/26 A Buy

Chief Executive Officer

60,000 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-2.36%-3.16%-6.95%+8.68% 249B
-1.61%+1.08%+38.64%+106.93% 1,060B
-0.76%-3.12%+35.78%+62.70% 623B
+0.39%+4.14%+17.00%+83.77% 480B
-0.29%-2.02%+62.52%+37.06% 352B
-2.03%+1.03%+22.25%+42.16% 345B
-1.92%-1.87%+11.94%+33.20% 274B
-1.37%-3.34%+37.86%+52.33% 223B
+0.17%-1.31%+25.96%+96.82% 182B
-1.58%-1.30%-33.48%-61.27% 168B
Average -1.18%-0.41%+21.15%+46.24% 395.61B
Weighted average by Cap. -0.82%+0.05%+27.85%+63.29%

Financials

2026 *2027 *
Net sales 63.16B 56.34B 52.51B 47.74B 89.83B 6,112B 90.79B 630B 246B 3,115B 237B 232B 9,969B 67.04B 59.8B 55.75B 50.68B 95.36B 6,489B 96.38B 668B 262B 3,307B 252B 246B 10,583B
Net income 11.9B 10.61B 9.89B 8.99B 16.92B 1,151B 17.1B 119B 46.42B 587B 44.65B 43.7B 1,878B 13.84B 12.34B 11.51B 10.46B 19.68B 1,339B 19.89B 138B 53.99B 683B 51.93B 50.82B 2,184B
Net Debt 19.66B 17.54B 16.35B 14.86B 27.96B 1,903B 28.26B 196B 76.71B 970B 73.78B 72.2B 3,103B 11.99B 10.69B 9.97B 9.06B 17.05B 1,160B 17.23B 119B 46.77B 591B 44.98B 44.02B 1,892B
Projected Income Statement - Annual - AstraZeneca PLC
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
08/10/26 GBX 11,892.00 -2.36% 2,276,973
07/10/26 GBX 12,180.00 +1.86% 1,721,629
06/10/26 GBX 11,958.00 +1.65% 2,189,051
05/10/26 GBX 11,764.00 -0.89% 1,619,067
02/10/26 GBX 11,870.00 -1.35% 1,659,276
Trader
Investor
Global
Quality
ESG MSCI
A
Ratings Surperformance© - AstraZeneca PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
157.15USD
Average target price
209.51USD
Spread / Average Target
+33.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - AstraZeneca PLC